Evidence map›Paper›PMID 40659855›Full record

ArticleActa pharmacologica Sinica2026

Discovery of selective GluN1/GluN3A NMDA receptor inhibitors using integrated AI and physics-based approaches.

Shi-Wei Li, Yue Zeng, Sa-Nan Wu, Xin-Yue Ma, Chao Xu, Zong-Quan Li, Sui Fang, Xue-Qin Chen, Zhao-Bing Gao, Fang Bai

Abstract read
In one paragraph

Article in Acta pharmacologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shi-Wei Li *Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, 201210, China.
Yue Zeng *State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Sa-Nan Wu *Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, 201210, China.
Xin-Yue Ma *School of Information Science and Technology, ShanghaiTech University, Shanghai, 201210, China.
Chao Xu *Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, 201210, China.
Zong-Quan Li *School of Information Science and Technology, ShanghaiTech University, Shanghai, 201210, China.
Sui FangState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Xue-Qin ChenState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Zhao-Bing GaoState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China. zbgao@simm.ac.cn.
Fang BaiShanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, 201210, China. baifang@shanghaitech.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

N-methyl-D-aspartate receptors (NMDARs) are glutamate-gated ion channels essential for synaptic transmission and plasticity in the central nervous system. GluN1/GluN3A, an unconventional NMDAR subtype functioning as an excitatory glycine receptor, has been implicated in mood regulation, with high expression in brain regions governing emotional and motivational states. However, therapeutic exploration has been significantly hindered by a lack of potent and selective modulators, limited structural data and the intrinsic complexity of ion channels. Here, we introduce a compound virtual screening pipeline that combines artificial intelligence and physical models, integrating two sequence-based deep learning prediction models (TEFDTA and ESMLigSite) with a molecular docking approach. This approach was employed to identify potential inhibitors against GluN1/GluN3A by screening a commercial database containing 18 million compounds. The strategy resulted in an impressive hit rate of 50% for discovering inhibitors, with the most promising compound exhibiting strong inhibitory activity (IC

Indexed as

Artificial IntelligenceDrug DiscoveryReceptors, N-Methyl-D-AspartateDeep LearningHumansMolecular Docking SimulationReceptors, N-Methyl-D-Aspartatebinding site identificationdeep learningGluN1/GluN3Amolecular dockingN-methyl-D-aspartate receptorsvirtual screening

Identifiers

PMID40659855
PMCPMC12764865

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.